Skip to main content


Pediatric Neuro-Oncology Tumor Board Quarterly Series

Pediatric SNO-Storm: A Collaborative Brainstorm Addressing Challenging Pediatric CNS Tumors from Around the World
Addressing the Spectrum of Spinal Ependymoma 

April 16, 2024, 12:30-2:00 pm ET

Register here!

This activity is provided by the Society for Neuro-Oncology.

Target Audience
Oncologists, Neuro-Oncologists, Neurosurgeons, Radiation Oncologists, Neurologists, Pathologists, Oncology and Neuro-oncology trainees, Oncology nurses and Nurse Practitioners. There is a pediatric focus to the presented material.

Statement of Need/Program Overview
With the release of the 2021 WHO CNS tumor classifications, classification of primary spinal ependymoma changed to better align with newly defined molecular subgroups. Ependymomas arising in the spine have been recognized to harbor key characteristics and epidemiology that better predict clinical outcome than histology/morphology alone. In this webinar, we intend to summarize the classifications of myxopapillary ependymoma (MPE), spinal ependymoma (SP-EPN), and spinal ependymoma MYCN-amplified (SP-MYCN), and as well as neurofibromatosis 2 (NF-2)-associated spinal ependymoma, to highlight clinical implications, treatment avenues, and future directions for targeted therapy. 

Educational Objectives 
After participating in this CME activity, participants should be able to:
  • Review the 2021 WHO CNS tumor classification of spinal ependymoma, including the impact of changes to molecularly defined subgroups and grading
  • Review key molecular and clinical characteristics of primary spinal ependymomas and their treatment approaches
  • Discuss the role of tumor predisposition testing in primary spinal ependymoma
Program Agenda
To view the program, click here. 

Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation 
The Society for Neuro-Oncology designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit, Claim Certificate of Participation
In order to receive credit or claim your certificate of participation for this activity, the participant must be logged into the webinar using their own registration login and complete the program evaluation. An individualized CME/CE evaluation link will be emailed to each participant at the conclusion of the webinar from The Society for Neuro-Oncology with the subject line "Instructions to Receive Credit for Addressing the Spectrum of Spinal Ependymoma webinar." 

For technical assistance with claiming CME credit, please email [email protected]  .

Deadline to claim CE Credit will be Wednesday May 15, 2024, at 11:59 pm ET.
Disclosure of Relevant Financial Relationships
The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. To view the disclosure list, click here. 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
SNO CME Contact Information
For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Ritterhouse, RN at [email protected]

Pediatric Tumor Board Webinar Leadership Team:
: Susan Chi, Erin Crotty, Adam Green

  • Andres Morales La Madrid, MD MHM, Sant Joan de Deu Pediatric Cancer Center Barcelona Children’s Hospital
  • Rosdali Diaz Coronado, MD, Universidad Peruana Cayetano Heredia
  • Karen Tsui, MD, Starship Blood and Cancer Centre
  • Nicholas Foreman, MD, University of Colorado
  • Katie Fehnel, MD, Boston Children’s Hospital, Harvard Medical School
  • Sanda Alexandrescu, MD, Boston Children’s Hospital
  • Suzanne Laughlin, MD, The Hospital for Sick Children
  • Shannon MacDonald, MD, Mass General Brigham
  • Ulrich Schuller, MD, University of Hamburg, Medical Center
  • Susan Chi, MD, Dana-Farber Cancer Institute
  • Adam Green, MD, University of Colorado School of Medicine
  • Erin Crotty, MD, Seattle Children’s Hospital, University of Washington School of Medicine